NeoGenomics, Inc. Proceeds from Lines of Credit
NeoGenomics, Inc. (NEO) reported Proceeds from Lines of Credit of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2021-02-25
- NeoGenomics, Inc. proceeds from lines of credit for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- NeoGenomics, Inc. proceeds from lines of credit for the quarter ending 2019-09-30 was $0.00.
- NeoGenomics, Inc. proceeds from lines of credit for the quarter ending 2018-12-31 was $5.00M.
- NeoGenomics, Inc. proceeds from lines of credit for the quarter ending 2018-09-30 was $0.00.
- NeoGenomics, Inc. proceeds from lines of credit for fiscal 2020 was $0.00.
- NeoGenomics, Inc. proceeds from lines of credit for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- NeoGenomics, Inc. proceeds from lines of credit for fiscal 2018 was $15.00M, a 500.96% increase from fiscal 2017.
- NeoGenomics, Inc. proceeds from lines of credit for fiscal 2017 was $2.50M.
| Period end | Proceeds from Lines of Credit 0 month | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $0.00 10-K · filed 2021-02-25 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $0.00 10-Q · filed 2019-11-13 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-07 | ||||
| 2018-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $5.00M derived: sum of 2 quarters · filed 2021-02-25 | $15.00M derived: sum of 3 quarters · filed 2021-02-25 | $15.00M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $10.00M derived: sum of 2 quarters · filed 2019-11-13 | $10.00M 10-Q · filed 2019-11-13 | $10.00M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $10.00M 10-Q · filed 2019-08-07 | $10.00M derived: sum of 3 quarters · filed 2020-02-28 | $7.50M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-08 | $0.00 derived: sum of 2 quarters · filed 2020-02-28 | -$2.50M derived: sum of 3 quarters · filed 2020-02-28 | -$2.51M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$2.50M derived: sum of 2 quarters · filed 2020-02-28 | -$2.51M derived: sum of 3 quarters · filed 2020-02-28 | $2.50M 10-K · filed 2020-02-28 | |
| 2017-09-30 | -$2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | -$2.51M derived: sum of 2 quarters · filed 2018-08-06 | $2.50M 10-Q · filed 2017-11-13 | ||
| 2017-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $5.00M 10-Q · filed 2018-08-06 | |||
| 2017-03-31 | $5.01M 10-Q · filed 2018-05-08 | ||||
| 2014-03-31 | $583.00K 10-Q · filed 2015-05-11 | ||||
| 2013-01-31 | $12.00M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |